Healthy Skepticism Library
Items published during the years 2000 to 2009
There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.
Page 131 of 144 pages ‹ First < 129 130 131 132 133 > Last ›
HSL10635
Dooley M.
Prescribing of warfarin, and brand selection [2]
Journal of Pharmacy Practice and Research 2003; 32:(4):259+261
HSL10636
Lubliner AA.
Are over-the-counter St. John's wort preparations as effective as assumed?
Deutsche Apotheker Zeitung 2003; 143:(1-2):50-52
HSL10638
Call for schering to repay NHS money over Yasmin claims
Pharmaceutical Journal 2003; 270:(7231):42
HSL10639
Pharmaceutical industry promotions criticised
Pharmaceutical Journal 2003; 270:(7231):42
HSL10644
Lucioni C, Mazzi S.
Prescription practice versus consuption standards with reference to proton pump inhibitors in Italy
PharmacoEconomics - Italian Research Articles 2003; 5:(1):3-10
HSL10645
Palmer JBD, Palmer RH.
Alosetron for irritable bowel syndrome [9] (multiple letters)
British Medical Journal 2003; 326:(7379):51-52
HSL10646
A measured response on medicines
Veterinary Record 2003; 152:(1):1-2
HSL10647
Thompson M.
Trends in claims for pharmacists' errors
Pharmaceutical Journal 2003; 270:(7230):
HSL10648
Drug price competition has little effect on NHS buying, PPRS study finds
Pharmaceutical Journal 2003; 270:(7230):
HSL11549
Miller D, Dinan W.
Global public relations and global capitalism
Demers D. Terrorism, Globalization and Mass Communication Spokane, WA: Marquette Books 2003
http://www.amazon.com/Terrorism-Globalization-Mass-Communication-Conference/dp/0922993041/ref=sr_1_1/102-5869202-0212934?ie=UTF8&s=books&qid=1190546162&sr=1-1
HSL11748
Reaves ND.
A model of effective health policy: the 1983 Orphan Drug Act.
J Health Soc Policy 2003; 17:(4):61-71
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17824591
HSL13205
Auvray L, Hensgen F, Sermet C.
La diffusion de l'innovation pharmaceutique en médecine libérale : revue de la littérature et premiers résultats français [Diffusion of pharmaceutical innovation in liberal medicine: revue of literature and first French results.]
Quest écon santé 2003; 73:1-8
http://cat.inist.fr/?aModele=afficheN&cpsidt=15305034
HSL13263
Bero L.
Implications of the tobacco industry documents for public health and policy.
Annu Rev Public Health 2003; 24:267-88
http://arjournals.annualreviews.org/doi/abs/10.1146%2Fannurev.publhealth.24.100901.140813
HSL13294
Mehrotra A, Dudley RA, Luft HS.
What's behind the health expenditure trends?
Annu Rev Public Health 2003; 24:385-412:
http://arjournals.annualreviews.org/doi/abs/10.1146%2Fannurev.publhealth.24.100901.141008
HSL16001
Nascimento A.
“AO PERSISTIREM OS SINTOMAS O MÉDICO DEVERÁ SER CONSULTADO”. ISTO É REGULAÇÃO?
INSTITUTO DE MEDICINA SOCIAL RIO DE JANEIRO: UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO 2003
Http://www4.ensp.fiocruz.br/visa/publicacoes/_arquivos/DissertacaoPropagandadeMedicamentos.doc
HSL16334
Blech J
Les inventeurs de maladies. Manœuvres et manipulations de l’industrie pharmaceutique. Paris: Actes Sud 2003
http://martinwinckler.com/article.php3?id_article=577
HSL16339
Greider K
The Big Fix: How the pharmaceutical industry rips off American consumers New York: Public Affairs 2003
http://www.amazon.com/Big-Fix-Pharmaceutical-Consumers-Publicaffairs/dp/1586481851
HSL16343
Healy D
Let them eat Prozac. Toronto: Lorrimer 2003
http://books.google.com.au/books?id=5w64WC_-jbMC&dq=Healy,+David.+Let+them+eat+Prozac.&printsec=frontcover&source=bn&hl=en&ei=g5yYSuG8DpKUkAWstsWrAg&sa=X&oi=book_result&ct=result&resnum=4#v=onepage&q=&f=false
HSL16348
Pignarre P
Le grand secret de l’industrie pharmaceutique Paris: La Découverte 2003
http://www.amazon.fr/grand-secret-lindustrie-pharmaceutique/dp/2707144398
HSL16924
Nascimento AC
'Ao persistirem os sintomas o médico deverá ser consultado'. Isto é regulação?
Instituto de Medicina Social da Universidade do Estado do Rio de Janeiro 2003;
http://www.scielo.br/scielo.php?pid=S0102-311X2006001200023&script=sci_arttext
HSL17363
Egilman D, Kim J, Biklen M.
Proving causation: the use and abuse of medical and scientific evidence inside the courtroom--an epidemiologist's critique of the judicial interpretation of the Daubert ruling.
Food Drug Law J 2003; 58:(2):223-50
http://www.ncbi.nlm.nih.gov/pubmed/12866555
HSL17715
Mahowald M, Bornemann M
Psychological aspects of gifts from drug companies
JAMA 2003; 298:(18):2404-2405
HSL17966
Bromley E, Metzl JM
Book Reviews: Prozac on the Couch: Prescribing Gender in the Era of Wonder Drugs : Duke University Press 2003
HSL18060
Smethurst D
Pharmaceutical medicine: making the leap
BMJ 2003; 327:s161-s162
http://archive.student.bmj.com/issues/04/02/careers/66.php
HSL18063
Moynihan R
Cochrane launches global consultation on drug company sponsorship
BMJ 2003; 327:(7423):1068
http://www.bmj.com/cgi/content/full/327/7423/1068
HSL18065
Dyer O
Lancet accuses AstraZeneca of sponsoring biased research
BMJ 2003; 327:(7422):1005
http://www.bmj.com/cgi/content/full/327/7422/1005-a
HSL18073
Relman A
Book review :Magic Cancer Bullet: How a Tiny Orange Pill Is Rewriting Medical History by Daniel Vesella
JAMA 2003; 290:(16):2194
http://jama.ama-assn.org/cgi/content/full/290/16/2194
HSL18111
Lynden B
Withdrawal of useful drugs from the market
Aust Prescr 2003; 26:50-1
http://www.australianprescriber.com/index.php?content=/magazines/vol26no3/50_51_editorial.htm
HSL18113
Dowden J
The story of one complaint
Aust Prescr 2003; 26:(3):
http://www.australianprescriber.com/index.php?content=/magazines/vol26no3/67_complaint.htm
HSL18176
Fava GA
Conflict of interest and the credibility of medical journals
Psychotherapy and Psychosomatics 2003; 12:1
HSL18185
Seaton A
Personal Views: 'There's none so blind as the double blind'.
BMJ 2003; 326:(7394):889
http://www.bmj.com/cgi/content/full/326/7394/889
HSL18190
Rector TS, Finch MD, Danzon, PM, Pauly MV, Manda BS
Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications
Medical Care 2003;
http://www.jstor.org/pss/3767849
HSL18193
Turone F
Italian police investigate GSK Italy for bribery
BMJ 2003; 326:(7386):413
http://www.bmj.com/cgi/content/extract/326/7386/413/a
HSL18225
Top 10 drugs
Australian Prescriber 2003; 26:(1):4
http://www.australianprescriber.com/magazine/20/4/artid/231
HSL18226
Fogg S
Informing the consumer
Aust Prescr 2003; 26:2-3
http://www.australianprescriber.com/magazine/26/1/2/3/
HSL18227
Sweet M
Gabapentin documents raise concerns about off-label promotion and prescribing
Aust Prescr 2003; 26:18-9
http://www.australianprescriber.com/magazine/26/1/18/9
HSL18228
Greed and Gabapentin
Aust Prescr 2003; 26:19
http://www.australianprescriber.com/magazine/26/1/artid/640/
HSL19048
Schwartz LM, Woloshin S.
On the prevention and treatment of exaggeration.
J Gen Intern Med 2003; 18:(2):153-4
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1494822/?tool=pubmed
HSL19391
Berndt E, Pindyck R, Azoulay P
Consumption externalities and diffusion in pharmaceutical markets: antiulcer drugs
The J Ind Econ 2003; 51:(2):243-270
http://www.nber.org/papers/w7772
HSL19517
Grande D
Cost and Quality of Industry-Sponsored Meals for Medical Residents
JAMA 2003; 290:(9):1150-1151
http://jama.ama-assn.org/content/290/9/1150.3.full
HSL19857
Burton B, Rowell A
Disease Mongering
PR Watch 2003; 10:(1):
http://www.prwatch.org/prwissues/2003Q1/monger.html
HSL19858
Burton B, Rowell A
From Patient Activism to Astroturf Marketing
PR Watch 2003; 10:(1):5
http://www.prwatch.org/prwissues/2003Q1/astroturf.html
HSL19859
Rowell A, Burton B
Clinically Suppressed
PR Watch 2003; 10:(1):7
http://www.prwatch.org/prwissues/2003Q1/suppressed.html
HSL17381
Schwab D
No letup in drug industry debate
Star-Ledger 2002 Dec 29
HSL2256
Jureidini J, Mansfield PR.
Avoiding competing interests
BMJ 2002 Dec 27; 325:(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL2490
Briggs DR.
The regulation of herbal medicines in Australia.
Toxicology 2002 Dec 27; 181-182:565-70
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12505367
HSL19519
Pear R
Drug Makers Battle A U.S. Plan to Curb Rewards for Doctors
The New York Times 2002 Dec 26
http://www.nytimes.com/2002/12/26/politics/26DRUG.html
HSL1923
Thorat MA .
Grading the competing interests
BMJ 2002 Dec 20; 325:(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL17385
Friscolanti M
Discount Drugs of Canada in Florida: 'Unlicensed pharmacies' spring up in Sunshine State
National Post 2002 Dec 20
HSL2005
Freudenheim M.
The Media Business: Advertising; Influencing Doctor's Orders
New York Times 2002 Dec 17
HSL2499
Ashcroft RE.
Conflicts of interest
BMJ 2002 Dec 17; 325:(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL19520
Relman AS, Angell M
America's Other Drug Problem: How the drug industry distorts medicine and politics.
The New Republic 2002 Dec 16
www.commercialalert.org/relmanangell.pdf
HSL2248
Kuczynski A.
Treating disease with a famous face.
New York Times 2002 Dec 15
http://www.nytimes.com/2002/12/15/fashion/15DISE.html
HSL1934
Smith R.
Making progress with competing interests.
BMJ 2002 Dec 14; 325:(7377):1375-6
http://bmj.com/cgi/reprint/325/7377/1375.pdf
HSL2483
Chaudhry S, Schroter S, Smith R, Morris J.
Does declaration of competing interests affect readers' perceptions? A randomised trial.
BMJ 2002 December 14; 325:1391-1392
http://bmj.com/cgi/content/full/325/7377/1391
HSL17881
Ferriman A
Novartis breached code after doctors say it 'invented' a disease
BMJ 2002 Dec 14; 325:(7377):1379
http://www.bmj.com/cgi/content/extract/325/7377/1379
HSL17882
Gottlieb S
Congress criticises drugs industry for misleading advertising
BMJ 2002 Dec 14; 325:(7377):1379
http://www.bmj.com/cgi/content/extract/325/7377/1379/a
HSL1812
Collective action is good for you
University of Sussex Bulletin 2002 Dec 12
http://www.sussex.ac.uk/press_office/bulletin/13dec02/article3.shtml
HSL1970
Petersen M.
Less return in marketing of medicines, a study says
New York Times 2002 Dec 12
http://www.nytimes.com/2002/12/12/business/12DRUG.html
HSL1033
Associated Press.
Ex-Lilly Workers Claim Corporate Backing
2002 Dec 11
HSL2001
Ex - Lilly Workers Claim Corporate Backing
THE ASSOCIATED PRESS 2002 Dec 11
HSL10669
Cohen GL.
Fiction: Off-label.
Neurology 2002 Dec 10; 59:(11):1818-20
http://www.neurology.org/cgi/content/full/59/11/1818
HSL1823
Hensley S.
When doctors go to class, industry often foots the bill: lectures tend to feature pills made by course sponsors; companies deny influence; a purple heartburn brochure.
Wall St J (East Ed) 2002 Dec 4; :A1,:
HSL2000
Warner J.
Misleading Drug Ads Persist
Medscape Medical News 2002 Dec 4
http://www.medscape.com/viewarticle/445686
HSL17380
Consumers Consider Prescription Drug Advertisements 'Useful,' Survey Finds
California Healthline 2002 Dec 4
HSL17390
Quick Take: New study finds DTC drive to Web yields new prescribers
Eyeforpharma.com 2002 Dec 3
http://www.eyeforpharma.com/print.asp?news=26635
HSL5378
Shilling C.
Culture, the 'sick role' and the consumption of health.
Br J Sociol 2002 Dec 01; 53:(4):621-38
http://journalsonline.tandf.co.uk/(20tfmkfypf4rf2vfye5dnqr2)/app/home/contribution.asp?referrer=parent&backto=issue,7,11;journal,5,20;linkingpublicationresults,1:103801,1
HSL1616
Tormala ZL, Petty RE.
What doesn't kill me makes me stronger: the effects of resisting persuasion on attitude certainty.
J Pers Soc Psychol 2002 Dec; 83:(6):1298-313
http://content.apa.org/journals/psp/83/6/1298
HSL1828
Chakrabarti A, Fleisher WP, Staley D, Calhoun L.
Interactions of staff and residents with pharmaceutical industry: a survey of psychiatric training program policies.
Ann R Coll Physicians Surg Can 2002 Dec; 35:(8):
HSL1846
Orme M, Frolich J, Vrhovac B; Education Sub-Committee of the European Association for Clinical Pharmacology and Therapeutics.
Towards a core curriculum in clinical pharmacology for undergraduate medical students in Europe.
Eur J Clin Pharmacol 2002 Dec; 58:(9):635-40
http://www.springerlink.com/app/home/contribution.asp?wasp=d5507396d41e4c958bbfd93f7f098d21&referrer=parent&backto=issue,11,12;journal,31,106;linkingpublicationresults,1:100413,1
HSL1848
Katz HP, Goldfinger SE, Fletcher SW.
Academia-industry collaboration in continuing medical education: description of two approaches.
J Contin Educ Health Prof 2002 Win; 22:(1):43-54
HSL2026
Miles MP, Munilla LS, Covin JG.
The Constant Gardener revisited: the effect of social blackmail on the marketing concept, innovation, and entrepreneurship.
J Bus Ethics 2002 Dec; 41:(3):287-95
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12755097
HSL2252
Klassen TP.
Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion?
Arch Pediatr Adolesc Med 2002 Dec; 156:(12):1180-1
http://archpedi.ama-assn.org/cgi/content/full/156/12/1180
HSL2456
Hollis A.
The importance of being first: evidence from Canadian generic pharmaceuticals.
Health Econ 2002 Dec; 11:(8):723-34
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12457372
HSL2495
Bessell TL, Silagy CA, Anderson JN, Hiller JE, Sansom LN.
Quality of global e-pharmacies: can we safeguard consumers?
Eur J Clin Pharmacol 2002 Dec; 58:(9):567-72
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12168510
HSL10475
Lampl C, Buzath A, Yazdi K, Sandor PS.
Ergot and triptan overuse in Austria--an evaluation of clinical data and cost.
Cephalalgia 2002 Dec; 22:(10):807-11
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1468-2982.2002.00442.x
HSL10652
Avouac B.
Prescribing outside the limits of marketing authorizations and reimbursement by the French universal health insurance system.
Joint Bone Spine 2002 Dec; 69:(6):534-7
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6W90-488N2YG-3&_user=10&_coverDate=12%2F31%2F2002&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=23cac00b44f2455dc037e841e18071f3
HSL10656
Carroll NV.
How effectively do managed care organizations influence prescribing and dispensing decisions?
Am J Manag Care 2002 Dec; 8:(12):1041-54
http://www.ajmc.com/Article.cfm?ID=113&CFID=8980495&CFTOKEN=81996035
HSL10658
Dargan P, Jones A.
Paracetamol: balancing risk against benefit.
QJM 2002 Dec; 95:(12):831-2
http://qjmed.oxfordjournals.org/cgi/content/full/95/12/831
HSL16362
Weatherby LB, Nordstrom BL, Fife D, Walker AM.
The impact of wording in 'Dear doctor' letters and in black box labels.
Clin Pharmacol Ther 2002 Dec; 72:(6):735-42
http://www.nature.com/clpt/journal/v72/n6/abs/clpt2002134a.html
HSL16745
Wolfe SM.
Drug safety withdrawals: who is responsible for notifying patients?
Pharmacoepidemiol Drug Saf 2002 Dec; 11:(8):641-2
http://www.ncbi.nlm.nih.gov/pubmed/12512237
HSL17883
Josefson D
Drug advertisers face scrutiny after potentially breaking FDA rules
BMJ 2002 Nov 30; 325:(7375):1262
http://www.bmj.com/cgi/content/extract/325/7375/1262/a
HSL1922
Vacheron-Trystram MN, Cheref S, Gauillard J, Plas J.
[A case report of mania precipitated by use of DHEA].
Encephale. 2002 Nov-Dec 28; 6:563-6
http://www.masson.fr/masson/portal/main_gab_art.ccn;jsessionid=E06B58A1556551049EE6D31F834D930B.mastin3?CodeProduct4=539&CodeRevue4=ENC&Path=REVUE/ENC/2002/28/6/ARTICLE111061972019.xml&Locations=
HSL2246
Labarre R.
Doctors and Industry
The New York Times 2002 Nov 28
http://www.nytimes.com/2002/11/28/opinion/L28DRUG.html
HSL1068
PR Newswire Association LLC
Pharmaceutical giants over-invest in promotion
2002 Nov 27
http://www.bioportfolio.com/news/report_1.htm
HSL1999
Zuckerman D.
Hype in Health Reporting
AlterNet 2002 Nov 25
http://www.alternet.org/story.html?StoryID=14638
HSL2469
Dukes MN.
Accountability of the pharmaceutical industry.
Lancet 2002 Nov 23; 360:(9346):1682-4
http://linkinghub.elsevier.com/retrieve/pii/S0140673602115996
HSL2251
Klausner JD, Kim A, Kent C.
Are HIV drug advertisements contributing to increases in risk behavior among men in San Francisco, 2001?
AIDS 2002 Nov 22; 16:(17):2349-50
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12441813
HSL3810
Petersen M.
Madison Ave. plays growing role in drug research
New York Times 2002 Nov 22
http://www.nytimes.com/2002/11/22/business/22DRUG.html
HSL1920
Vitry AI, Hurley E.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Med J Aust 2002 Nov 18; 177:(10):572-3
http://www.mja.com.au/public/issues/177_10_181102/vitry_181102.html
HSL3811
Gazarian M, Kaye KI.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Med J Aust 2002 Nov 18; 177:(10):572-3
HSL5454
Murphy S.
Gifts seen effective by drug company reps
Boston Globe 2002 Nov 17
HSL19521
Swidey N
The costly case of the purple pil
The Boston Globe 2002 Nov 17
http://www.boston.com/globe/magazine/2002/1117/coverstory.htm
HSL2459
Henry D, Lexchin J.
The pharmaceutical industry as a medicines provider.
Lancet 2002 Nov 16; 360:(9345):1590-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12443614
HSL3813
Smith R.
New BMJ policy on economic evaluations.
BMJ 2002 Nov 16; 325:(7373):1124
http://www.pubmedcentral.gov/articlerender.fcgi?tool=pubmed&pubmedid=12433741
HSL17885
Gottlieb S
Serious adverse events associated with perinatal drugs
BMJ 2002 Nov 16; 325:(7373):1132
http://www.bmj.com/cgi/content/extract/325/7373/1132
HSL2501
Abraham J.
The pharmaceutical industry as a political player.
Lancet 2002 Nov 9; 360:(9344):1498-502
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12433532
HSL17884
Campion EW.
Suspicions about the safety of vaccines.
N Engl J Med 2002 Nov 7; 347:(19):1474-5
http://content.nejm.org/cgi/content/extract/347/19/1474
HSL2006
Viva Viagra
2002 Nov 2
HSL2447
James A.
Medicines, society, and industry.
Lancet 2002 Nov 2; 360:(9343):1346
http://www.thelancet.com/journal/vol360/iss9343/full/llan.360.9343.editorial_and_review.22990.1
Page 131 of 144 pages ‹ First < 129 130 131 132 133 > Last ›
